September 23, 2014

Contact:   Kelly Peuquet
                 National Coalition on Health Care
                 [email protected]
                 202-638-7151, ext. 106

Without Changes, Proposed Labeling Rule Would Drive Up Costs for Consumers, Taxpayers 

Statement from National Coalition on Health Care President and CEO John Rother on the Proposed FDA Drug Labeling Rule

“Unless the FDA changes course, consumers and taxpayers will soon shoulder an additional $4 billion a year in drug costs. Worse, the FDA’s plan to allow different labels on brand name drugs and their generic competitors could confuse patients and their doctors—threatening patient safety.

Representative Steve Israel and Representative Tim Bishop should be commended for speaking out in their recent letter to the FDA. They join a growing chorus from stakeholders and elected officials of both parties who support a different approach. It’s time that the FDA heeded them.”

###

The National Coalition on Health Care(NCHC), the oldest and most diverse group working to achieve comprehensive health system reform, is a 501(c)(3) organization representing more than 80 participating organizations, including medical societies, businesses, unions, health care providers, faith-based associations, pension and health funds, insurers and groups representing consumers, patients, women, minorities and persons with disabilities. Member organizations collectively represent – as employees, members, or congregants – over 100 million Americans.

Some members of NCHC do not, or cannot, take positions either on specific legislation, strategies or on any policies outside their respective mission areas. However, all that can, do endorse broad policy positions in support of comprehensive health system change.

FILED UNDER: UNCATEGORIZED

Without Changes, Proposed Labeling Rule Would Drive Up Costs for Consumers, Taxpayers

SEPTEMBER 24, 2014 BY LARRY MCNEELY

“Unless the FDA changes course, consumers and taxpayers will soon shoulder an additional $4 billion a year in drug costs. Worse, the FDA’s plan to allow different labels on brand name drugs and their generic competitors could confuse patients and their doctors—threatening patient safety.

Representative Steve Israel and Representative Tim Bishop should be commended for speaking out in their recent letter to the FDA. They join a growing chorus from stakeholders and elected officials of both parties who support a different approach. It’s time that the FDA heeded them.”

See full press release: https://www.nchc.org/without-changes-proposed-labeling-rule-would-drive-up-costs-for-consumers-taxpayers